EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fatty acid synthase inhibitor cerulenin hinders liver cancer stem cell properties through FASN/APP axis as novel therapeutic strategies

Liang-Yun Chen, Dao-Sian Wu, Yao-An Shen

Journal of Lipid Research · 2024-11 · 65 (11) · 100660

DOI: 10.1016/j.jlr.2024.100660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2024-11. Verfasst von Liang-Yun Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Cerulenin, Neoplastic Stem Cells, Liver Neoplasms, Fatty Acid Synthase, Type I. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, Taipei Medical University, Taipei Medical University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) poses significant treatment challenges due to high postoperative recurrence rates and the limited effectiveness of targeted medications. Researchers have identified the unique metabolic profiles of cancer stem cells (CSCs) as the primary drivers of cancer recurrence, metastasis, and drug resistance. Therefore, to address the therapeutic conundrum, this study focused on rewinding metabolic reprogramming of CSCs as a novel therapeutic strategy. HCC CSCs exhibited elevated fatty acid (FA) metabolism compared with parental cells. To specifically target FA metabolism in CSCs, we utilized cerulenin, a fatty acid synthase (FASN) inhibitor. Surprisingly, cerulenin can diminish CSC-like characteristics, including stemness gene expression, spherogenicity, tumorigenicity, and metastatic potential. In addition, sorafenib, a multikinase inhibitor used as targeted therapy for advanced HCC, was employed in combination with cerulenin, demonstrating a great synergistic effect, particularly in CSCs. Importantly, our RNA sequencing analysis disclosed that the amyloid protein precursor (APP) is a crucial downstream effector of FASN in regulating CSC properties. We found that APP plays a crucial role in CSCs' characteristics that can be inhibited by cerulenin. By focusing on FA metabolism, this study identified the FASN/APP axis as a viable target to develop a more potent therapy strategy for advanced HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeruleninNeoplastic Stem CellsLiver NeoplasmsFatty Acid Synthase, Type IHumansMiceAnimalsCarcinoma, HepatocellularFatty Acid Synthesis InhibitorsFatty Acid SynthasesCell Line, Tumor

Stichwörter der Autor:innen

amyloid precursor proteincancer stem cellcombination therapyfatty acid metabolismliver cancer

Substanzen

CeruleninFatty Acid Synthase, Type IFASN protein, humanFatty Acid Synthesis InhibitorsFatty Acid Synthases

Autor:innen und Institutionen

  • Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Inter…

Förderung

  • Ministry of Science and Technology, Taiwan
  • Taipei Medical University
  • Taipei Medical University Hospital
  • National Science and Technology Council

Zitieren

APA

Chen, L. Y., Wu, D. S., & Shen, Y. A. (2024). Fatty acid synthase inhibitor cerulenin hinders liver cancer stem cell properties through FASN/APP axis as novel therapeutic strategies. Journal of Lipid Research, 65(11), 100660. https://doi.org/10.1016/j.jlr.2024.100660

Vancouver

Chen LY, Wu DS, Shen YA. Fatty acid synthase inhibitor cerulenin hinders liver cancer stem cell properties through FASN/APP axis as novel therapeutic strategies. Journal of Lipid Research. 2024;65(11):100660. doi:10.1016/j.jlr.2024.100660

BibTeX
@article{Chen2024,
  author = {Chen, Liang-Yun and Wu, Dao-Sian and Shen, Yao-An},
  title = {Fatty acid synthase inhibitor cerulenin hinders liver cancer stem cell properties through FASN/APP axis as novel therapeutic strategies},
  journal = {Journal of Lipid Research},
  year = {2024},
  volume = {65},
  number = {11},
  pages = {100660},
  doi = {10.1016/j.jlr.2024.100660}
}
Kostenlos starten →